חזרה לתוצאות החיפוש

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis

ישראלמגייס משתתפיםPHASE2

מצבים רפואיים

Scleroderma, Diffuse

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • UCLA, Los Angeles, California, United States

    Contact: Study coordinator (Lauren Nam) · lnam@mednet.ucla.edu
    Contact: Principal Investigator (Suzanne Kafaja)

  • UCSF, San Francisco, California, United States

    Contact: Study coordinator (Zilan Zheng) · Zilan.Zheng@ucsf.edu · 415-353-1301
    Contact: Principal Investigator (Emily Von Scheven)

  • UCSF, San Francisco, California, United States

    Contact: Study coordinator (Zilan Zheng) · zilan.zheng@ucsf.edu · 415-502-6627
    Contact: Principal Investigator (Emily Von Scheven)

  • Sutter Health Network, San Pablo, California, United States

    Contact: Study coordinator (Canary Jumawan) · canary.jumawan@sutterhealth.org
    Contact: Principal Investigator (Neftali Nevarez)

  • FL Medical Clinic Orlando Health, Zephyrhills, Florida, United States

    Contact: Study coordinator (William Daily Johnston) · william.johnston@orlandohealth.com · +1 813 782 1234
    Contact: Principal Investigator (Julio Gonzalez-Paoli)

  • Northwestern University, Chicago, Illinois, United States

    Contact: Study coordinator (Federica Sidoti) · Federica.sidoti@nm.org
    Contact: Principal Investigator (George Georges)

  • University Of Iowa, Iowa City, Iowa, United States

    Contact: Study coordinator (Darby Donovan) · darby-donovan@uiowa.edu · 319-356-2197
    Contact: Principal Investigator (Hanna Zembrzuska)

  • Boston Medical Center, Boston, Massachusetts, United States

    Contact: Study coordinator (Sarah Ebhodaghe) · sarah.ebhodaghe@bmc.org · 617-639-8760
    Contact: Principal Investigator (Marcin Trojanowski)

  • Michigan Med University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Abigail Mattison) · abimatti@med.umich.edu · 734-615-4762
    Contact: Principal Investigator (Monalisa Ghosh)

  • University of Minnesota, Minneapolis, Minnesota, United States

    Contact: Study coordinator (Amanda DeGrote) · Carl1032@umn.edu
    Contact: Principal Investigator (Hyun Kim)

  • James Cancer Hospital, Columbus, Ohio, United States

    Contact: Study coordinator (Claire Carlin) · Claire.Carlin@osumc.edu · 614-293-3196
    Contact: Principal Investigator (Ali Ajam)

  • Oregon Health Sciences University, Portland, Oregon, United States

    Contact: Study coordinator (Issabell Melz) · melz@ohsu.edu · 503-494-9021
    Contact: Principal Investigator (Atul Deodhar)

  • Avera Cancer, Sioux Falls, South Dakota, United States

    Contact: Study coordinator (Lauren Donelan) · lauren.donelan@avera.org · 605-322-3296
    Contact: Principal Investigator (Xavier Andrade-Gonzalez)

  • LDS Hospital, Salt Lake City, Utah, United States

    Contact: Study coordinator (Tara Sou) · tara.sou@imail.org · 801-408-1100
    Contact: Principal Investigator (Catherine Jennifer Bakewell)

  • Novartis Investigative Site, Camperdown, New South Wales, Australia

  • Novartis Investigative Site, Darlinghurst, New South Wales, Australia

  • Novartis Investigative Site, Graz, Austria

  • Novartis Investigative Site, Vienna, Austria

  • Novartis Investigative Site, Ghent, Belgium

  • Novartis Investigative Site, Salvador, Estado de Bahia, Brazil

  • Novartis Investigative Site, Barretos, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Olomouc, Czechia

  • Novartis Investigative Site, Prague, Czechia

  • Novartis Investigative Site, Aarhus N, Denmark

  • Novartis Investigative Site, Bordeaux, France

  • Novartis Investigative Site, Dijon, France

  • Novartis Investigative Site, Lille, France

  • Novartis Investigative Site, Lyon, France

  • Novartis Investigative Site, Montpellier, France

  • Novartis Investigative Site, Paris, France

  • Novartis Investigative Site, Rennes, France

  • Novartis Investigative Site, Freiburg im Breisgau, Baden-Wurttemberg, Germany

  • Novartis Investigative Site, Göttingen, Lower Saxony, Germany

  • Novartis Investigative Site, Leipzig, Saxony, Germany

  • Novartis Investigative Site, Halle, Saxony-Anhalt, Germany

  • Novartis Investigative Site, Jena, Thuringia, Germany

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Lübeck, Germany

  • Novartis Investigative Site, Mainz, Germany

  • Novartis Investigative Site, Nuremberg, Germany

  • Novartis Investigative Site, Ulm, Germany

  • Novartis Investigative Site, Debrecen, Hajdu Bihar Megye, Hungary

  • Novartis Investigative Site, Budapest, Hungary

  • Novartis Investigative Site, Haifa, Israel

  • Novartis Investigative Site, Ramat Gan, Israel

  • Novartis Investigative Site, Tel Aviv, Israel

  • Novartis Investigative Site, Ancona, AN, Italy

  • Novartis Investigative Site, Bergamo, BG, Italy

  • Novartis Investigative Site, Brescia, BS, Italy

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Milan, MI, Italy

  • Novartis Investigative Site, Pescara, PE, Italy

  • Novartis Investigative Site, Perugia, PG, Italy

  • Novartis Investigative Site, Pisa, PI, Italy

  • Novartis Investigative Site, Pavia, PV, Italy

  • Novartis Investigative Site, Roma, RM, Italy

  • Novartis Investigative Site, Udine, UD, Italy

  • Novartis Investigative Site, Sapporo, Hokkaido, Japan

  • Novartis Investigative Site, Sendai, Miyagi, Japan

  • Novartis Investigative Site, Suita, Osaka, Japan

  • Novartis Investigative Site, Bunkyo-ku, Tokyo, Japan

  • Novartis Investigative Site, Fukuoka, Japan

  • Novartis Investigative Site, Ishikawa, Japan

  • Novartis Investigative Site, Kyoto, Japan

  • Novartis Investigative Site, Utrecht, Netherlands

  • Novartis Investigative Site, Singapore, Singapore

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Seoul, South Korea

  • Novartis Investigative Site, Santiago Compostela, A Coruna, Spain

  • Novartis Investigative Site, Santander, Cantabria, Spain

  • Novartis Investigative Site, Pamplona, Navarre, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Barcelona, Spain

  • Novartis Investigative Site, Córdoba, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Madrid, Spain

  • Novartis Investigative Site, Málaga, Spain

  • Novartis Investigative Site, Salamanca, Spain

  • Novartis Investigative Site, Valencia, Spain

  • Novartis Investigative Site, Geneva, Switzerland

  • Novartis Investigative Site, Lausanne, Switzerland

  • Novartis Investigative Site, Zurich, Switzerland

  • Novartis Investigative Site, Taichung, Taiwan

  • Novartis Investigative Site, Sheffield, South Yorkshire, United Kingdom

מובילי המחקר

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)פנייה לחוקר (אימייל)